{"id":39850,"date":"2026-09-22T11:47:12","date_gmt":"2026-09-22T09:47:12","guid":{"rendered":"https:\/\/ggba.swiss\/aseptuva-moves-to-preclinical-validation-and-opens-a-chf-5-million-series-a-round\/"},"modified":"2026-09-22T11:50:10","modified_gmt":"2026-09-22T09:50:10","slug":"aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/","title":{"rendered":"Aseptuva passe \u00e0 la validation pr\u00e9clinique et ouvre un tour de s\u00e9rie A de CHF 5 millions"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.aseptuva.com\/\">Aseptuva<\/a>, une start-up medtech suisso-britannique, est pass\u00e9e du prototypage initial \u00e0 la validation pr\u00e9clinique en Europe gr\u00e2ce au tour d&rsquo;amor\u00e7age de CHF 2,4 millions boucl\u00e9 l&rsquo;an dernier. L&rsquo;entreprise d\u00e9veloppe une technologie de d\u00e9sinfection Far-UVC cibl\u00e9e, con\u00e7ue pour pr\u00e9venir les infections nosocomiales, en particulier les infections sanguines associ\u00e9es aux cath\u00e9ters intraveineux. En d\u00e9sinfectant directement le point d&rsquo;insertion du cath\u00e9ter au moyen de doses non canc\u00e9rig\u00e8nes de lumi\u00e8re Far-UVC, la technologie vise \u00e0 r\u00e9duire le risque infectieux et le recours aux antibiotiques, contribuant ainsi \u00e0 la lutte contre la r\u00e9sistance aux antimicrobiens.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le tour d&rsquo;amor\u00e7age a r\u00e9uni des personnalit\u00e9s reconnues du secteur de la sant\u00e9, dont Simon Michel, CEO d&rsquo;<a href=\"https:\/\/www.ypsomed.com\/\">Ypsomed<\/a>, bas\u00e9e \u00e0 Berthoud ; Roger Nitsch, CEO et pr\u00e9sident de <a href=\"https:\/\/neurimmune.com\/\">Neurimmune<\/a> ; Armin Diethelm, pr\u00e9sident d&rsquo;<a href=\"https:\/\/emitec-datacom.ch\/\">Emitec<\/a> ; le family office <a href=\"https:\/\/auxinam.com\/\">Auxinam<\/a> ; et le groupe d&rsquo;investissement <a href=\"https:\/\/we-invest.ch\/\">weInvest<\/a>. Les investisseurs existants <a href=\"https:\/\/www.valuemaker.ch\/\">Valuemaker<\/a> et <a href=\"https:\/\/41group.ch\/\">Fortyone<\/a> ont \u00e9galement particip\u00e9 au financement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Depuis, Aseptuva a men\u00e9 plus de 50 entretiens avec du personnel clinique dans huit h\u00f4pitaux en Europe et aux \u00c9tats-Unis afin d&rsquo;\u00e9tablir l&rsquo;ad\u00e9quation de son dispositif avec le march\u00e9. Le d\u00e9veloppement du produit a suivi un processus it\u00e9ratif avec Philips Innovation Services \u00e0 Eindhoven, le Fraunhofer FEP \u00e0 Dresde et le Laser Zentrum Hannover, aboutissant \u00e0 un prototype fonctionnel qui a depuis pass\u00e9 avec succ\u00e8s des tests d&rsquo;efficacit\u00e9 pr\u00e9cliniques au Royaume-Uni. Une \u00e9tude r\u00e9cente fond\u00e9e sur un mod\u00e8le de peau humaine en 3D n&rsquo;a mis en \u00e9vidence aucun effet biologique ind\u00e9sirable du traitement Far-UVC, ce qui \u00e9taye son innocuit\u00e9 dans les conditions test\u00e9es.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Un solide soutien scientifique et industriel<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Fond\u00e9e de mani\u00e8re ind\u00e9pendante en 2021 par ses trois fondateurs plut\u00f4t qu&rsquo;en tant que spin-off acad\u00e9mique, l&rsquo;entreprise a obtenu des financements comp\u00e9titifs d&rsquo;Innosuisse, d&rsquo;Horizon Europe, du National Institute for Health and Care Research britannique et d&rsquo;Innovate UK. En 2025, elle a <a href=\"https:\/\/ggba.swiss\/fr\/trois-innovateurs-de-suisse-occidentale-rejoignent-dimportants-programmes-europeens\/\">rejoint un projet Horizon Europe<\/a> dans le cadre du partenariat Transforming Health and Care Systems, recevant EUR 600&rsquo;000 pour d\u00e9velopper son dispositif destin\u00e9 aux unit\u00e9s de soins intensifs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ses conseillers comptent le Dr Hugo Sax, ancien pr\u00e9sident de Swissnoso, le Centre national suisse de pr\u00e9vention des infections ; le Dr Michael Hengartner, pr\u00e9sident du Conseil des EPF ; et le Dr Fabian Unteregger, copr\u00e9sident de Swiss Healthcare Startups. Le Dr Daniel Delfosse, ancien vice-directeur de Swiss Medtech, a rejoint le conseil d&rsquo;administration plus t\u00f4t cette ann\u00e9e.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le tour de s\u00e9rie A de CHF 5 millions soutiendra le d\u00e9veloppement clinique, l&rsquo;expansion au Royaume-Uni et la pr\u00e9paration de l&rsquo;entr\u00e9e sur le march\u00e9 am\u00e9ricain. Les actionnaires existants se sont d\u00e9j\u00e0 engag\u00e9s \u00e0 hauteur de plus de CHF 400&rsquo;000 de financement suppl\u00e9mentaire.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u00c0 la suite d&rsquo;un tour d&rsquo;amor\u00e7age de CHF 2,4 millions, la start-up medtech bernoise Aseptuva est pass\u00e9e du prototypage initial \u00e0 la validation pr\u00e9clinique de sa technologie Far-UVC destin\u00e9e \u00e0 pr\u00e9venir les infections sanguines li\u00e9es aux cath\u00e9ters, et l\u00e8ve d\u00e9sormais une s\u00e9rie A de CHF 5 millions.<\/p>\n","protected":false},"author":6,"featured_media":39847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1148,1188,1181,1163],"class_list":["post-39850","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-financing-fr-2","tag-healthcare-fr-2","tag-medical-devices-fr","tag-medtech-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa<\/title>\n<meta name=\"description\" content=\"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa\" \/>\n<meta property=\"og:description\" content=\"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-22T09:47:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-22T09:50:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Aseptuva passe \u00e0 la validation pr\u00e9clinique et ouvre un tour de s\u00e9rie A de CHF 5 millions\",\"datePublished\":\"2026-09-22T09:47:12+00:00\",\"dateModified\":\"2026-09-22T09:50:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\"},\"wordCount\":497,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg\",\"keywords\":[\"Financing\",\"Healthcare\",\"Medical Devices\",\"Medtech\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\",\"name\":\"Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg\",\"datePublished\":\"2026-09-22T09:47:12+00:00\",\"dateModified\":\"2026-09-22T09:50:10+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"L'\u00e9quipe d'Aseptuva, qui d\u00e9veloppe une technologie de d\u00e9sinfection Far-UVC cibl\u00e9e pour pr\u00e9venir les infections nosocomiales. | \u00a9 Aseptuva\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aseptuva passe \u00e0 la validation pr\u00e9clinique et ouvre un tour de s\u00e9rie A de CHF 5 millions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa","description":"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/","og_locale":"fr_FR","og_type":"article","og_title":"Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa","og_description":"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.","og_url":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-09-22T09:47:12+00:00","article_modified_time":"2026-09-22T09:50:10+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Aseptuva passe \u00e0 la validation pr\u00e9clinique et ouvre un tour de s\u00e9rie A de CHF 5 millions","datePublished":"2026-09-22T09:47:12+00:00","dateModified":"2026-09-22T09:50:10+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/"},"wordCount":497,"image":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg","keywords":["Financing","Healthcare","Medical Devices","Medtech"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/","url":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/","name":"Aseptuva passe en pr\u00e9clinique et ouvre une s\u00e9rie A | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg","datePublished":"2026-09-22T09:47:12+00:00","dateModified":"2026-09-22T09:50:10+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Aseptuva a atteint la validation pr\u00e9clinique de sa technologie de d\u00e9sinfection Far-UVC et ouvre un tour de s\u00e9rie A de CHF 5 millions.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/09\/Aseptuvea-Team-092026-1180x811-1.jpeg","width":1180,"height":811,"caption":"L'\u00e9quipe d'Aseptuva, qui d\u00e9veloppe une technologie de d\u00e9sinfection Far-UVC cibl\u00e9e pour pr\u00e9venir les infections nosocomiales. | \u00a9 Aseptuva"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/aseptuva-passe-a-la-validation-preclinique-et-ouvre-un-tour-de-serie-a-de-chf-5-millions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Aseptuva passe \u00e0 la validation pr\u00e9clinique et ouvre un tour de s\u00e9rie A de CHF 5 millions"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39850","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39850"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39850\/revisions"}],"predecessor-version":[{"id":39852,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39850\/revisions\/39852"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39847"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39850"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39850"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39850"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}